experimental group:Different targets -CART

2 trials

Sponsors

Beijing Gaobo Boren Hospital, Beijing Boren Hospital

Conditions

Relapsed/refractory central nervous system involvement of non-Hodgkin lymphomaT-cell lymphoma

Early Phase 1

Phase Ia/Ib, multicenter, open, non-randomized, single-arm clinical trial of humanized different-targeted chimeric antigen receptor T cells in the treatment of relapsed/refractory T-cell lymphoma

Active, not recruitingChiCTR2200058969

Beijing Gaobo Boren HospitalT-cell lymphoma

Start: 2022-04-21Updated: 2024-02-05

Different B-cell Target CAR T cells for relapsed/refractory central nervous system involved non-Hodgkin's Lymphoma (R/R CNSL)

Active, not recruitingChiCTR2200058972

Beijing Boren HospitalRelapsed/refractory central nervous system involvement of non-Hodgkin lymphoma

Start: 2022-04-30Updated: 2024-02-05

Related Papers

ASCT, CAR T-cell, or Combined Consolidation for R/R PCNSL in Re-achieved CR: An Inverse Probability of Treatment Weighting-Adjusted Comparative Study.

2026-07-17

Outcomes in patients with refractory/relapsed CNS lymphoma treated in complete remission: autologous transplantation vs. CAR-T therapy.

2026-03-24

CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: Single-arm, open-label, phase I study

Blood2025-11-03

Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy

Clinical Cancer Research2023-02-0327 citations

Interpreting Immune Reconstitution and Clinical Outcome By Single-Cell Transcriptomic Analysis in T-ALL Patients Undergoing Donor-Derived CD7 CAR-T Immunotherapy

Blood2022-11-151 citations